NASD · Healthcare · Diagnostics & Research · USA
Illumina Inc is a large cap company (market value between $10 billion and $200 billion) in the Diagnostics & Research industry.
Illumina develops sequencing and array-based systems, consumables, and analysis tools for genetic and genomic analysis. Its products serve genomic research centers, academic institutions, hospitals, and pharmaceutical and biotechnology companies across research and clinical markets including oncology, rare disease, and reproductive health.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Illumina Inc stock.
Overvalued: intrinsic value $62.48 per share, market price $262.66, margin of safety -320.4% (as of 2026-10-19).
Discounting its cash flows at 11.4% (average of 3 methods) values the shares at $62.48; the price of $262.66 is 320% above that value, and 68% of that value comes from beyond year five.
Leak Score: 58/100 on 12 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
16 more in this industry show a wider margin of safety.
ILMN is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 11.4% (average of 3 methods) values the shares at $62.48; the price of $262.66 is 320% above that value, and 68% of that value comes from beyond year five.
$62.48 per share (as of the 2026-10-19 close), against a market price of $262.66. That is a margin of safety of -320.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
58 out of 100, which we rate "Weak Signal", on 12 of 12 value investing signals.